As of October 24, 2026, retatrutide is not FDA-approved: FDA's Drugs@FDA data list no application for it.
TRIUMPH-1 (NCT05929066) is Eli Lilly's phase 3 trial of once-weekly retatrutide against placebo in adults without type 2 diabetes who have obesity or overweight. ClinicalTrials.gov lists 2,335 participants and the percent change in body weight from baseline to week 80 as a primary outcome.
In the published results, mean body weight fell 23.7% with retatrutide 9 mg and 25.0% with 12 mg, against 3.9% with placebo, over 80 weeks (treatment-regimen estimand).
member brief
the rest of this brief is for members.
free dispatches stay open to everyone. start with a free account, then unlock every brief with membership.
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.